Crinecerfont (English Wikipedia)
Analysis of information sources in references of the Wikipedia article "Crinecerfont" in English language version.
refsWebsite
Global rank
English rank
1st place
1st place
406th place
258th place
102nd place
76th place
fda.gov
- "FDA Approves New Treatment for Congenital Adrenal Hyperplasia". U.S. Food and Drug Administration (FDA) (Press release). 1 October 2024. Retrieved 16 December 2024.
This article incorporates text from this source, which is in the public domain. - "Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 1 October 2024. Retrieved 20 December 2024.
- New Drug Therapy Approvals 2024 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2025. Archived from the original on 21 January 2025. Retrieved 21 January 2025.
handle.net
hdl.handle.net
- World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82". WHO Drug Information. 33 (3). hdl:10665/330879.
nih.gov
dailymed.nlm.nih.gov
- "Crenessity- crinecerfont; capsule Crenessity- crinecerfont solution". DailyMed. 1 December 2024. Retrieved 25 January 2025.
prnewswire.com
- "Neurocrine Biosciences Announces FDA Approval of Crenessity (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia" (Press release). Neurocrine Biosciences. 13 December 2024. Retrieved 16 December 2024 – via PR Newswire.
web.archive.org
- New Drug Therapy Approvals 2024 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2025. Archived from the original on 21 January 2025. Retrieved 21 January 2025.